Thirty four out of 36 Granulosa cell tumours (32 out of 33 adult and 2 out 3 juvenile granulosa cell tumours), all cases of sertoli leydig cell tumours, three of fibroma/ thecoma cases and one case of microcystic stromal tumour.
Thirty fourcases of Granulosa cell tumour were stained for Inhibin, Calretinin and Cytokeratin.
1 They have reported 480 tumours over a 20 year period of which majority were adult granulosa cell tumour (43%), which is comparable to our study.
We have not reported any case of sclerosing stromal tumour of the ovary however these are reported in the literature.
We have also encountered a rare case of microcystic stromal tumour of the ovary.
Sex cord stromal tumours of the ovary are rare tumours, granulosa cell tumour being the commonest in our series which is comparable to international and regional data.
MagForce's patented absorption technology enables tumour cells to absorb these nanoparticles selectively.
The MFH(R) 300F system allows physicians to select the target temperature for the tumour and the nanoparticles can then be administered in conjunction with conventional chemotherapy techniques or in thermoablation modes for the destruction of tumour cells.
Irrespective of its location in the body, tumours are excited with nanoparticles by the MFH(R) 300F system.